Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11442)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Oct 10, 2016 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Avan A, Narayan R, Giovannetti E, Peters GJ. Role of Akt signaling in resistance to DNA-targeted therapy. World J Clin Oncol 2016; 7(5): 352-369 [PMID: 27777878 DOI: 10.5306/wjco.v7.i5.352] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v7/i5/352.htm |
| Number | Citing Articles |
| 1 |
Fatemeh Moosavi, Elisa Giovannetti, Godefridus J. Peters, Omidreza Firuzi. Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer. Critical Reviews in Oncology/Hematology 2021; 160: 103234 doi: 10.1016/j.critrevonc.2021.103234
|
| 2 |
Chi-Che Hsieh, Ting-Wei Li, Chun-Chun Li, Shang-Hung Chen, You-Lin Wei, Nai-Jung Chiang, Che-Hung Shen. DKK1 as a chemoresistant protein modulates oxaliplatin responses in colorectal cancer. Oncogenesis 2024; 13(1) doi: 10.1038/s41389-024-00537-y
|
| 3 |
Jan P. van Meerbeeck, Gerrit Jansen, Elisa Giovannetti, Godefridus J. Peters. Aminopeptidase antibodies in mesothelioma: new wine deserves new sacks. European Respiratory Journal 2018; 51(5): 1800817 doi: 10.1183/13993003.00817-2018
|
| 4 |
Shasha Yin, Liu Liu, Charles Brobbey, Viswanathan Palanisamy, Lauren E. Ball, Shaun K. Olsen, Michael C. Ostrowski, Wenjian Gan. PRMT5-mediated arginine methylation activates AKT kinase to govern tumorigenesis. Nature Communications 2021; 12(1) doi: 10.1038/s41467-021-23833-2
|
| 5 |
Sven de Mey, Inès Dufait, Mark De Ridder. Radioresistance of Human Cancers: Clinical Implications of Genetic Expression Signatures. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.761901
|
| 6 |
Swaathi Jayaraman, Xiaonan Hou, Mary J. Kuffel, Vera J. Suman, Tanya L. Hoskin, Kathryn E. Reinicke, David G. Monroe, Krishna R. Kalari, Xiaojia Tang, Megan A. Zeldenrust, Jingfei Cheng, Elizabeth S. Bruinsma, Sarah A. Buhrow, Renee M. McGovern, Stephanie L. Safgren, Chad A. Walden, Jodi M. Carter, Joel M. Reid, James N. Ingle, Matthew M. Ames, John R. Hawse, Matthew P. Goetz. Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer. Breast Cancer Research 2020; 22(1) doi: 10.1186/s13058-020-01286-7
|
| 7 |
Liu Liu, Xiaoming Dai, Shasha Yin, Pengda Liu, Elizabeth G. Hill, Wenyi Wei, Wenjian Gan. DNA-PK promotes activation of the survival kinase AKT in response to DNA damage through an mTORC2-ECT2 pathway. Science Signaling 2022; 15(715) doi: 10.1126/scisignal.abh2290
|
| 8 |
Barbora Adamová, Kamila Říhová, Jana Pokludová, Petr Beneš, Jan Šmarda, Jarmila Navrátilová. Synergistic cytotoxicity of perifosine and ABT‐737 to colon cancer cells. Journal of Cellular and Molecular Medicine 2023; 27(1): 76 doi: 10.1111/jcmm.17636
|
| 9 |
Franziska E. Marquard, Manfred Jücker. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. Biochemical Pharmacology 2020; 172: 113729 doi: 10.1016/j.bcp.2019.113729
|
| 10 |
Afsane Bahrami, Majid Khazaei, Malihe Hasanzadeh, Soodabeh ShahidSales, Mona Joudi Mashhad, Marjaneh Farazestanian, Hamid Reza Sadeghnia, Majid Rezayi, Mina Maftouh, Seyed Mahdi Hassanian, Amir Avan. Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer: Rational and Progress. Journal of Cellular Biochemistry 2018; 119(3): 2460 doi: 10.1002/jcb.25950
|
| 11 |
Nader Akbari Dilmaghani, Ava Safaroghli‐Azar, Atieh Pourbagheri‐Sigaroodi, Davood Bashash. The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies. IUBMB Life 2021; 73(4): 618 doi: 10.1002/iub.2446
|
| 12 |
Charu Guleria, Vanita Suri, Rakesh Kapoor, Ranjana Walker Minz, Ritu Aggarwal. Human papillomavirus 16 infection alters the Toll-like receptors and downstream signaling cascade: A plausible early event in cervical squamous cell carcinoma development. Gynecologic Oncology 2019; 155(1): 151 doi: 10.1016/j.ygyno.2019.07.023
|
| 13 |
Jim Moselhy, Suman Suman, Mohammed Alghamdi, Balaji Chandarasekharan, Trinath P. Das, Alatassi Houda, Murali Ankem, Chendil Damodaran. Withaferin A Inhibits Prostate Carcinogenesis in a PTEN-deficient Mouse Model of Prostate Cancer. Neoplasia 2017; 19(6): 451 doi: 10.1016/j.neo.2017.04.005
|
| 14 |
Sara M. Maloney, Camden A. Hoover, Lorena V. Morejon-Lasso, Jenifer R. Prosperi. Mechanisms of Taxane Resistance. Cancers 2020; 12(11): 3323 doi: 10.3390/cancers12113323
|
| 15 |
Kazuo Tomita, Manabu Fukumoto, Katsuhiko Itoh, Yoshikazu Kuwahara, Kento Igarashi, Taisuke Nagasawa, Masatoshi Suzuki, Akihiro Kurimasa, Tomoaki Sato. MiR-7-5p is a key factor that controls radioresistance via intracellular Fe2+ content in clinically relevant radioresistant cells. Biochemical and Biophysical Research Communications 2019; 518(4): 712 doi: 10.1016/j.bbrc.2019.08.117
|
| 16 |
L. Liu, B. Guo, Y. Han, S. Xu, S. Liu. MARCH1 silencing suppresses growth of oral squamous cell carcinoma through regulation of PHLPP2. Clinical and Translational Oncology 2022; 24(7): 1311 doi: 10.1007/s12094-021-02769-5
|
| 17 |
Lei Huang, Xiao-Ou Zhang, Esteban J. Rozen, Xiaomei Sun, Benjamin Sallis, Odette Verdejo-Torres, Kim Wigglesworth, Daniel Moon, Tingting Huang, John P. Cavaretta, Gang Wang, Lei Zhang, Jason M. Shohet, Mary M. Lee, Qiong Wu. PRMT5 activates AKT via methylation to promote tumor metastasis. Nature Communications 2022; 13(1) doi: 10.1038/s41467-022-31645-1
|
| 18 |
Gulam Mustafa Hasan, Md. Imtaiyaz Hassan, Sukhwinder Singh Sohal, Anas Shamsi, Manzar Alam. Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma. ACS Omega 2023; 8(30): 26685 doi: 10.1021/acsomega.3c02424
|
| 19 |
Godefridus J. Peters. Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies. 2020; : 1 doi: 10.1016/B978-0-12-819937-4.00001-7
|
| 20 |
Aleksandra Krajcer, Ewelina Grzywna, Joanna Lewandowska-Łańcucka. Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy. Biomedicine & Pharmacotherapy 2023; 165: 115174 doi: 10.1016/j.biopha.2023.115174
|
| 21 |
Kai-Ching Hsiao, Siou-Ying Ruan, Shih-Min Chen, Tai-Yu Lai, Ren-Hao Chan, Yan-Ming Zhang, Chien-An Chu, Hung-Chi Cheng, Hung-Wen Tsai, Yi-Fang Tu, Brian K. Law, Ting-Tsung Chang, Nan-Haw Chow, Chi-Wu Chiang. The B56γ3-containing protein phosphatase 2A attenuates p70S6K-mediated negative feedback loop to enhance AKT-facilitated epithelial-mesenchymal transition in colorectal cancer. Cell Communication and Signaling 2023; 21(1) doi: 10.1186/s12964-023-01182-5
|
| 22 |
Christopher E. Eyermann, John D. Haley, Evguenia M. Alexandrova. The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer. Cell Death & Disease 2021; 12(1) doi: 10.1038/s41419-021-03414-3
|
| 23 |
Mahrou Vahabi, Bilal Dehni, Inés Antomás, Elisa Giovannetti, Godefridus J. Peters. Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma. Cancer and Metastasis Reviews 2023; 42(3): 725 doi: 10.1007/s10555-023-10127-w
|
| 24 |
Annette A. van Zweeden, Roza C.M. Opperman, Richard J. Honeywell, Godefridus J. Peters, Henk M.W. Verheul, Hans J. van der Vliet, Dennis Poel. The prognostic impact of circulating miRNAs in patients with advanced esophagogastric cancer during palliative chemotherapy. Cancer Treatment and Research Communications 2021; 27: 100371 doi: 10.1016/j.ctarc.2021.100371
|
| 25 |
George M. Ramzy, Laura Boschung, Thibaud Koessler, Céline Delucinge-Vivier, Mylène Docquier, Thomas A. McKee, Laura Rubbia-Brandt, Patrycja Nowak-Sliwinska. FOLFOXIRI Resistance Induction and Characterization in Human Colorectal Cancer Cells. Cancers 2022; 14(19): 4812 doi: 10.3390/cancers14194812
|
| 26 |
Adel I. Alalawy. Key genes and molecular mechanisms related to Paclitaxel Resistance. Cancer Cell International 2024; 24(1) doi: 10.1186/s12935-024-03415-0
|
| 27 |
Cristina Cuesta, Cristina Arévalo-Alameda, Esther Castellano. The Importance of Being PI3K in the RAS Signaling Network. Genes 2021; 12(7): 1094 doi: 10.3390/genes12071094
|
| 28 |
Gopal P. Pathak, Rashmi Shah, Barry E. Kennedy, J. Patrick Murphy, Derek Clements, Prathyusha Konda, Michael Giacomantonio, Zhaolin Xu, Isabel R. Schlaepfer, Shashi Gujar. RTN4 Knockdown Dysregulates the AKT Pathway, Destabilizes the Cytoskeleton, and Enhances Paclitaxel-Induced Cytotoxicity in Cancers. Molecular Therapy 2018; 26(8): 2019 doi: 10.1016/j.ymthe.2018.05.026
|
| 29 |
Paul Noordhuis, Adrianus C. Laan, Kasper van de Born, Richard J. Honeywell, Godefridus J. Peters. Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines. International Journal of Molecular Sciences 2019; 20(15): 3619 doi: 10.3390/ijms20153619
|
| 30 |
Shaoxin Cai, Xuefei Cheng, Yi Liu, Zhizun Lin, Wei Zeng, Changshun Yang, Lihang Liu, Ozor Anthony Chukwuebuka, Weihua Li. EYA1 promotes tumor angiogenesis by activating the PI3K pathway in colorectal cancer. Experimental Cell Research 2018; 367(1): 37 doi: 10.1016/j.yexcr.2018.02.028
|
| 31 |
Jiang Du, Xiupeng Zhang, Haijing Zhou, Yuan Miao, Yong Han, Qiang Han, Enhua Wang. Alex3 suppresses non–small cell lung cancer invasion via AKT/Slug/E-cadherin pathway. Tumor Biology 2017; 39(7): 101042831770144 doi: 10.1177/1010428317701441
|
| 32 |
Sreyashi Bhattacharya, Hannah L. Harris, Ridwan Islam, Sanika Bodas, Navatha Polavaram, Juhi Mishra, Dipanwita Das, Parthasarathy Seshacharyulu, Achyuth Kalluchi, Anirban Pal, Manish Kohli, Subodh M. Lele, Michael Muders, Surinder K. Batra, Paramita M. Ghosh, Kaustubh Datta, M. Jordan Rowley, Samikshan Dutta. Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers. Cell Death & Disease 2024; 15(8) doi: 10.1038/s41419-024-06916-y
|
| 33 |
Mahendra Jadhao, Eing-Mei Tsai, Ho-Chun Yang, Yih-Fung Chen, Shih-Shin Liang, Tsu-Nai Wang, Yen-Ni Teng, Hurng-Wern Huang, Li-Fang Wang, Chien-Chih Chiu. The Long-Term DEHP Exposure Confers Multidrug Resistance of Triple-Negative Breast Cancer Cells through ABC Transporters and Intracellular ROS. Antioxidants 2021; 10(6): 949 doi: 10.3390/antiox10060949
|
| 34 |
Isabell Götting, Verena Jendrossek, Johann Matschke. A New Twist in Protein Kinase B/Akt Signaling: Role of Altered Cancer Cell Metabolism in Akt-Mediated Therapy Resistance. International Journal of Molecular Sciences 2020; 21(22): 8563 doi: 10.3390/ijms21228563
|
| 35 |
Fatemeh Ghaemimanesh, Majid Mehravar, Saeideh Milani, Ensieh M. Poursani, Kioomars Saliminejad. The multifaceted role of sortilin/neurotensin receptor 3 in human cancer development. Journal of Cellular Physiology 2021; 236(9): 6271 doi: 10.1002/jcp.30344
|
| 36 |
Afsane Bahrami, Majid Khazaei, Soodabeh Shahidsales, Seyed Mahdi Hassanian, Malihe Hasanzadeh, Mina Maftouh, Gordon A. Ferns, Amir Avan. The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress. Journal of Cellular Biochemistry 2018; 119(1): 213 doi: 10.1002/jcb.26136
|
| 37 |
Zechen Zhao, Weiming Chu, Yang Zheng, Chao Wang, Yuemei Yang, Teng Xu, Xueming Yang, Wei Zhang, Xu Ding, Gang Li, Hongchuang Zhang, Junbo Zhou, Jinhai Ye, Heming Wu, Xiaomeng Song, Yunong Wu. Cytoplasmic eIF6 promotes OSCC malignant behavior through AKT pathway. Cell Communication and Signaling 2021; 19(1) doi: 10.1186/s12964-021-00800-4
|
| 38 |
Abdulmelik Aytatli, Neslisah Barlak, Fatma Sanli, Hasan Onur Caglar, Betul Gundogdu, Arzu Tatar, Michael Ittmann, Omer Faruk Karatas. AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer. Cellular Oncology 2022; 45(1): 41 doi: 10.1007/s13402-021-00645-6
|
| 39 |
Navid Sobhani, Giandomenico Roviello, Silvia P. Corona, Maurizio Scaltriti, Anna Ianza, Marina Bortul, Fabrizio Zanconati, Daniele Generali. The prognostic value of PI3K mutational status in breast cancer: A meta‐analysis. Journal of Cellular Biochemistry 2018; 119(6): 4287 doi: 10.1002/jcb.26687
|
| 40 |
Wen Pan, Yangyi Wang, Guiyuan Chen, Xiaopeng Ma, Yuanzeng Min. A carrier-free nanovaccine combined with cancer immunotherapy overcomes gemcitabine resistance. Biomaterials 2025; 313: 122788 doi: 10.1016/j.biomaterials.2024.122788
|
| 41 |
Parastoo Modarres, Farzaneh Mohamadi Farsani, Amir Abas Nekouie, Sadeq Vallian. Meta-analysis of gene signatures and key pathways indicates suppression of JNK pathway as a regulator of chemo-resistance in AML. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-91864-2
|
| 42 |
Katherine Shishido, Alexis Reinders, Swapna Asuthkar. Epigenetic regulation of radioresistance: insights from preclinical and clinical studies. Expert Opinion on Investigational Drugs 2022; 31(12): 1359 doi: 10.1080/13543784.2022.2158810
|
| 43 |
Rosa Wijnen, Camilla Pecoraro, Daniela Carbone, Hamid Fiuji, Amir Avan, Godefridus J. Peters, Elisa Giovannetti, Patrizia Diana. Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC). Cancers 2021; 13(17): 4389 doi: 10.3390/cancers13174389
|
| 44 |
Yufei Tang, Shaoqi Zong, Hailun Zeng, Xiaofeng Ruan, Liting Yao, Susu Han, Fenggang Hou. MicroRNAs and angiogenesis: a new era for the management of colorectal cancer. Cancer Cell International 2021; 21(1) doi: 10.1186/s12935-021-01920-0
|
| 45 |
Chan Il Kim, Sooheon Kim, Seong‐Min Park, Sung Soo Kim, Hyung Joon Kwon, Weiwei Lin, Saewhan Park, Seokjun Ha, Kyung Hee Ha, Sanha Park, Seung Min Park, Tae Hoon Kim, Kyung‐Hee Kim, Yun‐Hee Kim, Jong Heon Kim, Jong Bae Park. Fam20C Kinase as a Key Regulator of Bevacizumab Resistance in Mesenchymal Glioblastoma. Advanced Therapeutics 2024; 7(2) doi: 10.1002/adtp.202300309
|
| 46 |
Marika A. Frańczak, Claudine van der Sande, Elisa Giovannetti, Godefridus J. Peters. Effects of nucleoside analogues, lipophilic prodrugs and elaidic acids on core signaling pathways in cancer cells. Nucleosides, Nucleotides & Nucleic Acids 2024; 43(8): 851 doi: 10.1080/15257770.2024.2339952
|
| 47 |
Jennifer A. Waters, Ixchel Urbano, Mikella Robinson, Carrie D. House. Insulin-like growth factor binding protein 5: Diverse roles in cancer. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.1052457
|
| 48 |
C. G. Da Silva, Godefridus J. Peters, Ferry Ossendorp, Luis J. Cruz. The potential of multi-compound nanoparticles to bypass drug resistance in cancer. Cancer Chemotherapy and Pharmacology 2017; 80(5): 881 doi: 10.1007/s00280-017-3427-1
|
| 49 |
Robin Van Den Borg, Alessandro Leonetti, Marcello Tiseo, Elisa Giovannetti, Godefridus J. Peters. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine. Expert Review of Anticancer Therapy 2019; 19(6): 461 doi: 10.1080/14737140.2019.1624530
|
| 50 |
Hai Huang, Jun-Koo Yi, Su-Geun Lim, Sijun Park, Haibo Zhang, Eungyung Kim, Soyoung Jang, Mee-Hyun Lee, Kangdong Liu, Ki-Rim Kim, Eun-Kyong Kim, Youngkyun Lee, Sung-Hyun Kim, Zae-Young Ryoo, Myoung Ok Kim. Costunolide Induces Apoptosis via the Reactive Oxygen Species and Protein Kinase B Pathway in Oral Cancer Cells. International Journal of Molecular Sciences 2021; 22(14): 7509 doi: 10.3390/ijms22147509
|